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To determine the cost and benefits of an intensive diabetes
education programme for patients with prolonged self-management




Sixty-one participants of a multidisciplinary intensive diabetes
education programme (MIDEP) were measured before they started the
intervention (T0), and at 1-year follow-up (T1). Data on glycaemic control
(HbA1c), diabetes-related distress (PAID) and costs were obtained.
Changes over time were analysed and means at T0 and T1 were compared
to a reference group of 230 non-referred consecutive outpatients. The
number  needed  to  treat  (NNT),  that  is,  the  number  of  patients  to  be
treated to achieve one successful case, was calculated for different baseline




Diabetes-related costs decreased significantly and participants
improved significantly in HbA1c and diabetes-related distress following
MIDEP. HbA1c and distress reached the levels of the reference group. The
T1 costs remained higher than in the reference group, but the reduction in









40 would improve the NNT to achieve
clinically relevant outcomes, while 76% of the patients matched these inclu-




MIDEP is effective in improving glycaemic
control and diabetes-related distress for patients with prolonged self-
management difficulties. Besides the immediate reduction in costs found in
the present study, improved glycaemic control may reduce future costs of
diabetic  complications.  Stricter  inclusion  criteria  with  respect  to  HbA1c




Diabetes mellitus is a growing public health issue
(Mandrup 1998), predominantly because of the
growing prevalence of type 2 diabetes and to a lesser
extent by the increasing prevalence of type 1 diabetes
(International Diabetes Federation 2003). Diabetes
requires a complex and demanding treatment and




. 2003) and gener-
ates high direct and indirect medical costs (Niessen &
Casparie 2001). Both in type 1 and type 2 diabetes,
poor glycaemic control resulting in prolonged high
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blood glucose levels (measured by glycated haemo-
globin: HbA1c) is strongly related to the develop-
ment of diabetic complications [Diabetes Control
and Complications Trial Research Group (DCCT)
1993; UKPDS 1998], such as retinopathy, neuropathy
and cardiovascular disease. These complications are
associated with high medical costs (DCCT 1996), dis-
ability and a reduction in quality of life (DCCT 1996;
Rubin & Peyrot 1999; UKPDS 2000).
Maintaining acceptable blood-glucose levels
largely depends on self-management, which requires
daily and life-long efforts from patients. They have to
inject insulin or take blood-glucose-lowering tablets,
keep a healthy and regular diet and exercise regu-
larly and above all balance these elements in any
possible situation. For example, stress influences

























Besides avoiding high blood-glucose levels in order
to prevent long-term diabetic complications, the
occurrence of hypoglycaemia (too low blood glucose
levels) causes several immediate inconvenient
effects, ranging from dizziness to coma. Hypoglycae-




. 1994). A dilemma, however, is that tight glycae-
mic control increases the number of hypoglycaemic
episodes (UKPDS 1998). Given the heavy demands
diabetes puts on patients, it is not surprising that a
considerable number of diabetic patients experience
difficulties in maintaining adequate self-manage-








. 2000) and psychosocial dis-










Interventions to improve glycaemic control may
help to prevent long-term complications, which may,
in the long term, lead to cost savings that outweigh





. 2002). The investment costs and post-
poned benefits, however, can present a major barrier




. 1999), although a few intervention studies
showed more immediate cost reductions. Testa &
Simonson (1998) conducted a medical intervention
that resulted in improved glycaemic control, which
led to beneficial labour-related outcomes and less
ambulatory care visits compared to a placebo group.
Some studies showed that lifestyle interventions for
diabetic patients reduced medical costs and are cost-
effective within a reasonably short time frame by
reducing hospital admissions and unplanned visits to








. 2001). Lifestyle interventions conducted in






To support patients with prolonged self-






















. 2004a), based on









. 2000). MIDEP resulted in improved





. 2003). Several important elements that
contribute to the effectiveness of diabetes lifestyle
interventions were incorporated in the design of the
programme. MIDEP goes beyond improving knowl-
edge, because mere knowledge does not result in
improved glycaemic control nor behaviour change
(Clement 1995; Coates & Boore 1996; Brown 1999)
and isolated diabetes educational interventions




.  2001). To achieve durable changes in self-
management, changes in patients’ attitudes and
motivation are more important than purely improv-




. 2001). Thus, interven-
tion programmes must focus on patients’ personal
lifestyles, respect individual habits, incorporate
social support and be reinforced over time (Ander-
son 1990). Treatment that combines attention to gly-
caemic and psychosocial factors is likely to be most
effective, which requires close collaboration between
diabetologists, diabetes nurse specialists, psycholo-
gists and other team members (Snoek & Skinner
2002). The contents of MIDEP will be discussed in




 section. Obviously, such a
relatively time-consuming and expensive interven-
tion should be reserved for patients at particular
high risk and for whom intensive standard care




. 1999), that is, regular
medical check-ups and consultations of a diabetes
nurse specialist, is insufficient.
Careful selection of patients and an estimation of
the costs in relation to its effects is needed to opti-
mize MIDEP’s efficiency. Therefore, we studied
firstly the cost-effectiveness of the education pro-
gramme by comparing costs and savings of the inter-
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vention. Secondly, we determined the patients for
whom the intervention was most effective in achiev-





The multidisciplinary intensive diabetes 
education programme
 
The Centre for Rehabilitation of the Groningen Uni-
versity Hospital offers an MIDEP for patients with
diabetes mellitus with prolonged self-management
difficulties manifesting in poor glycaemic control or
diabetes-related psychosocial problems. Patients are
referred from most outpatient clinics in the region.
Figure 1 gives an outline of the programme. MIDEP
comprises a core module of 10 whole days of group
sessions (fixed groups of six to nine patients) and
some individual support in a 10-week period. Follow-
up visits take place at 6 and 12 weeks and 1 year after
the core module, of which the 1-year follow-up ses-
sion is not considered treatments, because it is used
only for receiving and giving feedback and patients
return to regular diabetes care after the second fol-
low-up visit. In effect, participants are withdrawn
from their regular outpatient care for a period of
5 months. The diabetes education team consists of a
diabetes nurse specialist, an endocrinologist, a dieti-
cian, a social worker, a psychologist, a physiothera-
pist, an occupational therapist and an activity
therapist, who work together closely.
The programme aims to empower patients to set
and attain their own treatment goals. MIDEP high-
lights a range of diabetes-related topics and has
sessions on self-management, diet, exercise, daily
activities and employment, psychosocial aspects of
diabetes and behavioural coping strategies. The pro-
gramme uses a four-phase learning sequence. First a
topic is introduced, followed by group discussion or
practice. In the third phase, patients plan how to fit in
a certain aspect in their own daily lives, which will
subsequently be evaluated in the fourth phase. Using
this approach, the patients’ own experiences and
goals that patients set at admission to MIDEP are
taken into account. We provided an educational
framework that covers all relevant topics of diabetes
self-management, because education directed solely
at patients’ own priorities contains a risk of missing









Of the 80  patients  who  had  an  admission  interview
of MIDEP, 11 did not start MIDEP or prematurely
aborted the programme within the first 3 weeks.
HbA1c was obtained from all 69 participants who
completed MIDEP. Sixty-three patients completed
the questionnaire at T1 and 56 patients completed
cost  questionnaires  at  both  T0  and  T1.  A  total  of
330 consecutive non-referred outpatients from the
Groningen University Hospital diabetes clinic were
approached to serve as a reference group, using the
same exclusion criteria as MIDEP. A total of 230
patients (70%) gave informed consent, their HbA1c
values were obtained and they completed the same
questionnaire as MIDEP participants did.
 
Glycaemic control and diabetes-related distress
 
Glycaemic control was measured by means of
HbA1c, a standard measure in diabetes for the per-
centage of glycated haemoglobin, indicating glycae-




8.0% is considered to reflect poor glycaemic control
(American Diabetes Association 2001). The number
of hypoglycaemia during the previous 4 weeks and
the number of severe hypoglycaemia for which assis-
tance was required were obtained by self-reports.











Figure 1 Schedule of the 
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sured the diabetes-related distress. The PAID con-
sists of 20 Likert scale items and has subscales for
‘diabetes-related emotional problems’ (12 items),
‘treatment-related problems’ (three items), ‘food-
related problems’ (three items) and ‘social support-
related problems’ (two items) and the 20 items can be
summed to a total diabetes distress score. All scales
range from 0 to 100, with higher scores indicating













Effects of MIDEP were determined by comparing
means of HbA1c, hypoglycaemia and PAID scores at





tests. The magnitude of the changes was quantified by
calculating effect sizes (ES), which were obtained by
dividing the mean change (T1–T0) by the standard
deviation (SD) of that change. ESs of around 0.20 are
considered small, ESs of around 0.50 medium and
ESs of around 0.80 are considered large (Cohen
1992). Severe hypoglycaemia were expected to occur
only  in  a  relatively  small  part  of  the  patients and
to be non-normally distributed. For these reasons,
the percentage of patients having 1 or more severe
hypoglycaemia was calculated. The participants of
MIDEP were compared with the reference group of






The number needed to treat (NNT), a measure of
treatment success, is the number of patients who
need to be treated in order to have a successful treat-





& Sackett 1995). The NNT was determined for a clin-
ically relevant improvement in HbA1c and in the
total PAID score. The criteria for successful treat-





HbA1c, which is considered clinically relevant (Dia-
betes Control & Complications Trial Research
Group 1993; Cook & Sackett 1995), or a 1-year post-




8.0%, considered fair glycae-
mic control (American Diabetes Association 2001).
The criteria for successful treatment in diabetes-
related distress were a reduction in PAID scores of 1









. 2000)] were used as criteria for successful
treatment.





























50 were calculated to determine success rates
when these different inclusion criteria would have
been applied. In addition, we calculated the NNT for





in HbA1c and/or 1 SD improvement in the total
PAID score. NNTs were determined for all partici-









40. The NNT for
the combined criteria indicates the ratio of patients
who were successfully treated with respect to at least




The aim of the economic evaluation was to assess the
costs of MIDEP per patient. The economic evalua-
tion was based on the data gathered for 69 pro-
gramme participants and 230 non-participants from
the diabetes outpatient department of the University
Hospital. They filled in a cost questionnaire allowing
an economic evaluation from a limited societal
perspective.  Both  direct  medical  costs  and  direct
and indirect non-medical costs were included as
described below. In addition to the questionnaire
data, expert opinions from two experienced diabetol-
ogists were obtained regarding time spent on out-
patient visits by various disciplines.
Programme  costs  were  calculated  on  the  basis of
a programme schedule provided by the centre for
rehabilitation, detailing the time spent by the various
disciplines involved. Programme overhead costs
(rooms, cleaning, etc.) were  calculated  by  means  of
a 35% surcharge on total personnel costs. This was
not applied for costs of the use of sports and fitness
facilities as well as swimming pool, for which current
rental rates were used. For the calculation of costs
per patient an average group size of seven patients
was applied.
Costs of hospital admission were calculated on the
basis of the actual number of admission days and the
recommended Dutch unit price (indexed to price
levels of the year 2003) for hospitalization per day for





. 2000). For health care consumption out-
side of the hospital, the recommended Dutch unit
price for a GP visit was used. For consultation by
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telephone, half the price of a visit was used. Travel
costs were calculated on the basis of distances from
postal code to postal code and data on mode of trans-
portation used by the patients. For data on the latter,
61 randomly chosen programme participants were
interviewed separately. All 230 patients in the refer-
ence group also provided these data. The costs of
productivity losses were calculated according to the
friction cost method, on the basis of data regarding
sick leave from the questionnaire. Standard prices
from the Dutch guideline, specified by sex and age,
were used.
The costs of following the education programme
were compared to the difference in health care con-
sumption costs between T0 and T1. For the follow-
up period, costs for successful and unsuccessful
patients were compared as well. Participants were
considered to be withdrawn from regular care while
following the programme. The follow-up consisted
of two 6-month assessments, totalling 1 year.
Because of the short time horizon discounting was
not applied.
 
Statistical testing of costs
 
The effects in diabetes-related costs were tested non-
parametrically, because the distributions of cost data
were skewed. We used Wilcoxon signed rank tests,





-test, to compare pre- and post-measures of
costs for outpatient clinic contacts, general practitio-
ner contacts, hospital admissions, direct non-medical
costs, indirect non-medical costs and total costs. To
test differences in the reduction of the total costs for
patients who were successfully treated by MIDEP
and those who were not, Mann–Whitney tests for two






Fifty-six of the 69 participants of MIDEP filled in a
questionnaire at both T0 and T1, which means a
response rate of 81%. HbA1c was obtained from all
69 participants at both measurements. Table 1 pre-
sents demographic characteristics of the participants
and the 230 outpatients. Participants of MIDEP were
more recently diagnosed, which was not considered





1 years). No other significant
differences in demographics were found between
participants and the consecutive outpatients.
 
Effects of MIDEP on glycaemic control, 
diabetes-related distress and cost parameters
 
One  year  after  the  intervention,  the  participants
of MIDEP had improved significantly on most
measures for glycaemic control, diabetes distress
(Table 2), and medical costs (Table 3). At T0, partic-
ipants of MIDEP had worse glycaemic control and
more diabetes-related distress than the reference
group. One year post-MIDEP, participants did not
differ significantly from the reference group in any of
these measures.
The costs for hospital admissions, costs for outpa-
tient clinic contacts and the indirect non-medical
costs declined considerably in the participants of
MIDEP (see Table 3). Totalled up, at T1 the costs
measured per patient were €
 
1469 lower than costs
generated in the year previous to MIDEP. The non-
parametric tests (Wilcoxon singed ranks tests) show
that the ranks of the post-MIDEP costs are signifi-
 


































Type of diabetes (% type 1/type 2) 63/37 68/32




SD) 13 ± 11* 18 ± 13
Employed (%) 65 55
Living with a partner (%) 78 76
MIDEP, multidisciplinary intensive diabetes education programme.
*P < 0.05.
J.C. Keers et al.
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cantly lower than the pre-MIDEP ranks of costs, but
the magnitude of the differences in means could not
be tested. Both at T0 and T1, participants generated
significantly more costs than the reference group.
However, the differences in costs became much
smaller at T1.
Table 4 shows that the total costs of MIDEP were
€1327, consisting of €1023 for running the pro-
gramme and of €304 for travel expenses. The costs of
MIDEP were compensated by the reduction in costs
between T0 and T1.
Number needed to treat
Table 5 shows that in all MIDEP participants the
NNT for a ≥0.5% HbA1c reduction was 2.88, which
means that to realize this target in one patient, 2.88
patients had to be treated. One in every 2.09 patients
had an HbA1c of <8.0% at T1. One in every 1.64
patients achieved at least one of both targets. Fur-
thermore, Table 4 shows that patients with a higher
HbA1c at inclusion have lower NNTs for the target
of ≥0.50 reduction. However, less patients would
achieve an HbA1c <8.0%.
In general, the NNTs for PAID scores were lower
than for HbA1c targets; a higher percentage of
patients achieved the targets in diabetes distress.
Overall, one in every 2.24 patients achieved a reduc-
tion of >1 SD (≥18) of the reference group and one in
every 1.19 patients achieved a PAID score <40.
Including patients with baseline scores of, respec-
tively, ≥30, ≥40 or ≥50 would lead to a substantial
decline in the NNT for a > 1 SD reduction without a
large increase of the NNT for the <40 target (see
Table 5).
Combining the success criteria for HbA1c and
PAID (an improvement of ≥0.5 HbA1c or ≥18 points
at the overall PAID score or both), an NNT of 1.80
(95% CI = 1.46–2.41) for all participants of MIDEP
was found, that is, one in every 1.80 patients
improved relevantly in at least one of the two main
outcomes. Seventy-six percent of the participants had
a baseline HbA1c ≥ 8.0% and/or baseline PAID ≥ 40.
The NNT for the combined outcome in this subgroup
of patients was 1.48 (95% CI = 1.23–1.95). For a
≥0.5% HbA1c reduction alone the NNT was 2.38
(95% CI = 1.73–3.71) and for ≥18 reduction at the
PAID the NNT was 1.72 (95% CI = 1.37–2.38).
NNT and cost reductions
The comparisons of subgroups based on the success
criteria for clinically relevant reductions in HbA1c
and or diabetes-related distress revealed some inter-
esting associations between clinical outcomes of
MIDEP and cost reductions, expressed as the mean





HbA1c (n = 69) 8.5 ± 1.3** 8.1 ± 1.2 0.32** 8.0 ± 1.2
Number of hypoglycaemia§ 9.3 ± 8.1** 5.7 ± 5.9 0.53*** 5.6 ± 6.8
≥1 severe hypoglycaemia§ 18% 12% – 14%
PAID (n = 56)
PAID total 38 ± 22*** 22 ± 15 0.81*** 25 ± 18
Emotional problems 44 ± 26*** 25 ± 16 0.88*** 29 ± 21
Treatment-related problems 28 ± 22*** 20 ± 17 0.40** 20 ± 22
Food-related problems 31 ± 24*** 21 ± 19 0.44** 22 ± 21
Social support-related problems 22 ± 26** 12 ± 19 0.57*** 13 ± 21
MIDEP, multidisciplinary intensive diabetes education programme.
*P < 0.05; **P < 0.01; ***P < 0.001.
†Means compared to the reference group by independent samples t-tests.
‡Effect sizes calculated by dividing the mean change by the SD of that change, and significances of differences between pre- and post-
measurement were calculated with paired samples t-tests.
§In past 4 weeks.
Costs and benefits of intensive diabetes education
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total costs at T1 minus the mean total costs at T0
(costs mentioned in Table 3). Patients with a clini-
cally relevant reduction in HbA1c had a mean reduc-
tion in costs of €2144 in the year post-MIDEP,
compared to €509 in the group of patients that did
not achieve this improvement in HbA1c (P = 0.30;
Mann–Whitney test). Comparing subgroups of par-
ticipants who did achieve a ≥1 SD reduction in PAID
and those who did not, gave similar results: a €2535
reduction was found in patients with relevant PAID
improvement compared to €408 in the patient not
achieving this PAID reduction (P = 0.088). Combin-
Table 3 Average diabetes-related costs per MIDEP participant in the year pre-MIDEP (T0) and the year post-MIDEP (T1)
T0 (n = 56)
(€)
T1 (n = 56)
(€) P-value*
Reference group (n = 230)
(€)
Outpatient clinic contacts
Mean ± SD 49 ± 58 29 ± 21 0.003 23 ± 21
Median 27 18 18
n¢ 0 0 0
P-value† <0.001 <0.001
Diabetes-related general practitioner contacts
Mean ± SD 20 ± 43 6 ± 19 0.013 9 ± 37
Median 0 0 0
n¢ 34 47 187
P-value† <0.001 0.46
Diabetes-related hospital admissions
Mean ± SD 1357 ± 4588 718 ± 2994 0.035 48 ± 389
Median 0 0 0
n¢ 42 50 224
P-value† <0.001 0.006
Direct non-medical costs (travel expenses)
Mean ± SD 23 ± 23 16 ± 12 0.002 20 ± 51
Median 18 12 6
n¢ 0 0 0
P-value† <0.001 <0.001
Diabetes-related indirect non-medical costs (friction costs)
Mean ± SD 1472 ± 4165 929 ± 3452 0.15 158 ± 945
Median 0 0 0
n¢ 45 46 206
P-value† 0.073 0.107
Total
Mean ± SD 2991 ± 6174 1522 ± 5021 0.001 289 ± 1050
Median 126 73 55
n¢ 0 0 0
P-value† <0.001 0.001
MIDEP, multidisciplinary intensive diabetes education programme; n¢, number of patients generating no costs.
*Wilcoxon signed ranks test comparing T1 with T0.
†Mann–Whitney test comparing participants of MIDEP with the reference group.
Table 4 Costs of MIDEP per participant
Costs




Use of facilities €13
Travel expenses €304
Total €1327
MIDEP, multidisciplinary intensive diabetes education programme.
J.C. Keers et al.
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ing the criteria for HbA1c and PAID gave a €2025
reduction for the successfully treated patients and a
€499 reduction for the non-successfully treated
patients (P = 0.13). In sum, patients achieving clini-
cally relevant outcomes in HbA1c and PAID had
greater, although not statistically significant, cost
reductions than patients who did not achieve these
HbA1c and PAID outcomes.
Discussion
The present study shows beneficial effects of an
MIDEP for patients with prolonged diabetes self-
management difficulties 1-year post-treatment. An
improvement in glycaemic control, as indicated by
the reduction in HbA1c, and a reduction in diabetes-
related distress were found. These improvements
were achieved for reasonable intervention costs that
were outweighed by the substantial reduction in costs
generated by participants in the year post-MIDEP.
The high costs MIDEP participants generated in
the year before the intervention were substantially
reduced, although remaining significantly higher
than the costs of the reference group. The reduc-
tion in costs measured in this study equalled the
costs of the intervention. Because the participants
were withdrawn from their regular diabetes care
during MIDEP, they did not generate outpatient
clinic costs, direct non-medical costs and patients
had no hospital admissions during approximately
5 months. The net costs of MIDEP then would be
lower than €1327, which means a further improve-
ment of the programme’s cost-effectiveness. A rela-
tively small proportion of the MIDEP participants
generated the major part of the costs. The non-
parametric tests performed on this skewed data
confirmed that the observed differences in mean
costs indeed indicate lower diabetes-related costs
post-treatment.
The present study does not give an exhaustive
description of the cost involved in diabetes care, but
the most important variable costs in these relatively
young diabetic patients without established diabetic
complications were measured. We did not measure
the costs for materials used for self-testing of blood
glucose, although the improved HbA1c in the
MIDEP participants could suggest an increase in
self-testing. In our opinion however, these costs
would be relatively small in comparison to for
instance the costs of hospital admissions. The
improved HbA1c, when sustained over time, will
greatly reduce future health care costs by lowering
Table 5 Number needed to treat for various inclusion criteria of HbA1c and PAID score
HbA1c







all patients 69 (100) 2.09 (1.66–2.81) 2.88 (2.12–4.22) 1.64 (1.38–2.07)
HbA1c ≥ 7.5 54 (78) 2.70 (1.95–4.13) 2.70 (1.95–4.13) 1.86 (1.48–2.53)
HbA1c ≥ 8.0 44 (64) 3.14 (2.10–5.39) 2.20 (1.63–3.30) 1.91 (1.48–2.73)
HbA1c ≥ 8.5 31 (45) 3.88 (2.23–8.53) 1.94 (1.43–3.04) 1.94 (1.43–3.04)








all patients 56 (100) 1.19 (1.08–1.40) 2.24 (1.71–3.20) 1.08 (1.02–1.21)
PAID total ≥ 30 31 (55) 1.24 (1.08–1.60) 1.41 (1.16–1.93) 1.07 (1.01–1.28)
PAID total ≥ 40 27 (48) 1.27 (1.09–1.70) 1.17 (1.04–1.49) 1.08 (1.01–1.32)
PAID total ≥ 50 14 (25) 1.40 (1.09–2.41) 1.17 (1.01–1.77) 1.08 (1.00–1.53)
CI, confidence interval.
*SD of reference group.
Costs and benefits of intensive diabetes education
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the risks for diabetic complications (DCCT 1993;
UKPDS 1998).
From  an  efficiency  perspective,  not  only  the
cost-effectiveness of the intervention is a matter of
concern. The growing prevalence of diabetes (Inter-
national Diabetes Federation 2003) puts an increas-
ing load on outpatient diabetes clinics with some
subgroups of patients showing a pattern of increased
health care utilization (El Fakiri et al. 2003). The tar-
get group of MIDEP demands particularly much
care, with more outpatient visits and more patients
having hospital admissions than average outpatients
do. Taking over this care for 5 months produces a
considerable temporally relief of the outpatient clinic
in itself besides the more lasting reduction of health
care consumption of these patients after MIDEP.
Besides determining the costs and benefits of
MIDEP, an important aim of the present study was to
determine for which patients the programme is most
effective in achieving clinically relevant improve-
ments in HbA1c and diabetes-related distress. The
effect of MIDEP in HbA1c and diabetes-related dis-
tress were satisfying in the whole group of partici-
pants, with one in less than three patients having a
≥0.5% reduction in HbA1c and one in slightly more
than two patients reporting a decrease of >1 SD at
the PAID (diabetes-related distress). Nevertheless,
the selection of patients with higher baseline HbA1c
and higher baseline distress would lead to lower
NNT to achieve clinically relevant improvements.
With respect to HbA1c, selection of patients with
HbA1c ≥ 8.0% does result in a fairly considerable
reduction in the NNT. Further restriction of inclusion
on basis of HbA1c would not lead to large improve-
ments of MIDEP’s efficacy on glycaemic control
outcomes. Interestingly, guidelines of the American
Diabetes Association define an HbA1c ≥ 8.0% as
poor control (American Diabetes Association 2001).
The NNTs for >1 SD reduction in PAID scores
declined considerably when selecting patients on,
respectively, baseline scores of ≥30 and ≥40, without
the NNTs for achieving PAID scores < 40 increasing
much. In patients with high diabetes-related distress
indicated by PAID scores ≥ 40 (Snoek et al. 2000),
one in every 1.17 achieved a >1 SD reduction and
one in every 1.27 achieved a PAID score of <40 at 1-
year follow-up. Using these two inclusion criteria
would further increase MIDEP’s efficiency without
excluding many patients; 76% of the participants had
either HbA1c ≥ 8.0% and/or PAID ≥ 40.
Participants of MIDEP with clinical relevant
improvements in HbA1c and/or diabetes-related dis-
tress had a greater reduction in the diabetes-related
costs than patients who did not improve relevantly.
Decreasing the NNT by stricter selection of patients
as shown in Table 4, thus would not only increase
MIDEP’s effectiveness in glycaemic control and
diabetes-related distress, but in cost-effectiveness as
well. In successfully treated patients, the costs of
running MIDEP, being €1327, are more than com-
pensated by the costs reductions, whereas for non-
successfully treated patients this is not the case.
Policy implications
To conclude with, this present study hands some
valuable clues for the improvement of outpatient
care for diabetic patients with prolonged self-
management problems, both from the patients’ per-
spective and from a cost-effectiveness perspective.
The postponed cost reduction of diabetes interven-
tions can present a serious barrier for implementa-
tion of the intervention (Sadur et al. 1999). Like a few
other interventions (Testa & Simonson 1998; Sadur
et al. 1999), we found MIDEP to be cost-effective
within a year, which makes it an attractive interven-
tion for patients with prolonged self-management
difficulties. This holds not only for patients with poor
glycaemic control (Sadur et al. 1999), but also for
patients with diabetes-related distress. In contrast to
most other cost-effectiveness studies of diabetes
interventions, this study focused not only on the effi-
cacy of the intervention, but also on improving this
efficacy by exploring optimal inclusion criteria for
MIDEP.
The present study shows that MIDEP results in
clinically relevant improvements while the pro-
gramme costs were almost entirely compensated by
reduced medical consumption in the year post-
MIDEP. The effects in the patients-related outcomes
glycaemic control and diabetes-related distress can
be further enhanced by selecting patients with either
HbA1c ≥ 8.0% or PAID scores ≥ 40. With this, the
reduction in diabetes-related medical and non-
medical costs will further improve as well. Using
these criteria more strictly in clinical practice can
J.C. Keers et al.
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help to solve another efficiency problem in the utili-
zation of additional diabetes care for patients with
self-management problems as well, that is, non-
referral of patients who are actually in need of addi-
tional care. In particular, patients with high levels of
diabetes-related distress are not recognized as need-
ing MIDEP at the outpatient clinic (Keers et al.
2004b), although the present study shows beneficial
effects for these patients as well.
Intensive outpatient programmes can improve dia-
betes care and relieve the occupied outpatient clinics
that have to treat the growing number of diabetic
patients. For this, these programmes have to be
focused on patients with prolonged high levels of dia-
betes self-management problems and who generate
high costs even without having established diabetes
complications yet.
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